A carregar...
Oestrogen and zoledronic acid driven changes to the bone and immune environments: Potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre- and post-menopausal conditions
Late stage breast cancer commonly metastasises to bone and patient survival averages 2–3 years following diagnosis of bone involvement. One of the most successful treatments for bone metastases is the bisphosphonate, zoledronic acid (ZOL). ZOL has been used in the advanced setting for many years whe...
Na minha lista:
| Publicado no: | J Bone Oncol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Elsevier
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7516134/ https://ncbi.nlm.nih.gov/pubmed/32995253 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jbo.2020.100317 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|